Clinical Trial Update: Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of Longidaza for residual lung changes after COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Polymyositis
• Post-acute Sequelae of Sars-cov-2 Infection
• Pulmonary Fibrosis

Drugs mentioned

• Longidaza

Snippet

Sponsor: NPO Petrovax | Conditions: Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis | Phase 3 | Status: COMPLETED